OrthoPediatrics Corp. (KIDS) PT Raised to $72 at Truist Securities Following Earnings

Truist Securities analyst Kaila Krum raised the price target on OrthoPediatrics Corp. (NASDAQ: KIDS) to $72.00 (from $64.00) while maintaining a Buy rating.

The analyst commented, "KIDS reported 1Q results with revenue of $21.5 million beating the Cons. $19.9 million estimate. The low-end of guidance was lifted and growth is now expected to be 32-38% this year. Our key takeaway is less on the quarter and more on the company's outlook. We see KIDS beginning to hit an inflection point, as it evolves from an innovative share taker into a true leader in pediatric orthopedics. Led by ApiFix, Orthex, a strong core business and an emerging pipeline, we see tangible catalysts that could drive upside to 2022 numbers and accelerate growth long term. Maintain BUY; PT to $72 PT."

You May Also Be Interested In

• HSBC Downgrades Anglo American Platinum Limited (AMS:SJ) (ANGPY) to Reduce
• BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
• Sanofi (SAN:FP) (SNY) PT Raised to EUR114 at Bernstein SocGen Group